Anne F. Luetkemeyer

country of citizenship: United States of America

educated at: Calvert School, Stanford University, Harvard Medical School, University of California, San Francisco

occupation: infectious disease physician

Annie F. Luetkemeyer is an American physician and researcher who is Professor of Medicine and Infectious Diseases at the University of California, San Francisco. She specializes in infectious diseases, in particular tuberculosis, human immunodeficiency virus and viral hepatitis. During the COVID-19 pandemic Luetkemeyer led a clinical trial of remdesivir. She has also researched treatment of COVID-19 as a co-infection with HIV. Source: Wikipedia (en)

Series

There is nothing here

Create a new serie

Works

There is nothing here

Create a new work

Articles 61

Date

Title

Authors

2020-03-01

Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections

Anne F. Luetkemeyer, John Kaldor, Connie Celum, Jean-Michel Molina
2020-07-15

Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV

Paul E Sax, Anne F. Luetkemeyer
2020-12-04

Retrospective-Prospective Study of Safety and Efficacy of Sofosbuvir based Direct Acting Antivirals in HIV/HCV Coinfected Participants with Decompensated Liver Disease Pre or Post Liver Transplant

Marion G Peters, Norah A Terrault, Christine M. Durand, Peter G Stock, Anne F. Luetkemeyer, Mark Sulkowski, Emily A Blumberg, Jean Emond
2020-12-11

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Andre C Kalil, Myoung-don Oh, Seow Yen Tan, John H. Beigel, Anne F. Luetkemeyer, Kay M Tomashek, Nadine Rouphael, David C. Lye
2019-04-01

CROI 2019: highlights of viral hepatitis.

Anne F. Luetkemeyer, David L Wyles
2019-04-19

A pilot metabolomics study of tuberculosis immune reconstitution inflammatory syndrome

Anne F. Luetkemeyer, Diane Havlir
2019-12-01

HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era

Anne F. Luetkemeyer, Mallory O Johnson
2019-03-04

Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences

Anne F. Luetkemeyer, Mallory O Johnson
2018-03-16

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study

Matthew P Kosloski, Anne F. Luetkemeyer, Mark Sulkowski, Robert Flisiak, Jürgen Rockstroh, Kenneth E Sherman, Roger Trinh, Jihad Slim, Ruth Soto-Malave, Sanjay Bhagani, Nancy S Shulman
2018-05-01

CROI 2018: Highlights of Viral Hepatitis.

Anne F. Luetkemeyer, David L Wyles
2018

Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection

Anne F. Luetkemeyer
2018-06-01

Localized US Efforts to Eliminate Hepatitis C

Shelley N Facente, Anne F. Luetkemeyer, Emalie Huriaux
2018-10-01

Association of Rapid Molecular Testing With Duration of Respiratory Isolation for Patients With Possible Tuberculosis in a US Hospital

Anne F. Luetkemeyer, Marguerite Roemer, Lelia H Chaisson, Adithya Cattamanchi, Margaret A Handley
2018-02-01

A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT)

Anne F. Luetkemeyer
2017-07-01

Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens

Anne F. Luetkemeyer, David L Wyles
2017-08-07

Impact of Larger Sputum Volume on Xpert® MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis

Beatriz Grinsztejn, Anne F. Luetkemeyer, Ian Sanne, Cynthia Firnhaber, Evelyn Hogg, Gerald H Mazurek, Debra A Benator, David Alland, Sharlaa Badal-Faesen
2017-07-07

Grazoprevir, Ruzasvir, and Uprifosbuvir for HCV After NS5A Treatment Failure

Stefan Zeuzem, Anne F. Luetkemeyer, David L Wyles, Heiner Wedemeyer, Ira M Jacobson
2017-05-01

CROI 2017: Highlights of Advances in Viral Hepatitis and Liver Fibrosis

Anne F. Luetkemeyer, David L Wyles
2017-03-29

Sofosbuvir and Velpatasvir for the Treatment of HCV in Patients Coinfected with HIV-1: an Open-Label, Phase 3 Study

Anne F. Luetkemeyer, Shyam Kottilil, David L Wyles, Mark Sulkowski, Norbert Bräu, Kimberly Workowski, Diana M Brainard, John G McHutchison, Susanna Naggie
2017-02-17

Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients

Adriano Lazzarin, Anne F. Luetkemeyer, Jean-Michel Molina
2017-09-23

Disabling Dactylitis and Tenosynovitis Due to Mycobacterium haemophilum in a Patient With Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome

Michael H Woodworth, Anne F. Luetkemeyer
2017-07-22

Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.

Tami Pilot-Matias, Adriano Lazzarin, Anne F. Luetkemeyer, Chloe Orkin, Jürgen Rockstroh, David L Wyles, Roger Trinh, Linda M Fredrick, Ruth Soto-Malave, Sanjay Bhagani, Nancy S Shulman, Pierre-Marie Girard
2017-11-01

Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials

Anne F. Luetkemeyer
2016-06-10

A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries

Anne F. Luetkemeyer, Susan Swindells, Robert W Coombs
2016-07-01

Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells

Diane Havlir, Anne F. Luetkemeyer, Richard A Koup, Prudence Ive
2016-02-01

The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection

Pablo Tebas, Anne F. Luetkemeyer
2016-02-02

Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings

Beatriz Grinsztejn, Anne F. Luetkemeyer, Cynthia Firnhaber, Diane Havlir, Susan Swindells, Gerald H Mazurek, Debra A Benator, David Alland
2016-01-14

Tuberculosis Infection in Early Childhood and the Association with HIV-exposure in HIV-uninfected Children in Rural Uganda

Carina Marquez, Grant Dorsey, Moses R Kamya, Anne F. Luetkemeyer, Edwin D Charlebois, Diane Havlir, Gabriel Chamie, Jane Achan, Jaffer Okiring
2016-03-29

12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens

Anne F. Luetkemeyer
2016-05-01

CROI 2016: Viral Hepatitis and Liver Fibrosis

Anne F. Luetkemeyer, David L Wyles
2016-08-09

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.

Anne F. Luetkemeyer, David C. Nickle, Frederick L Altice, Gregory J Dore, Jason Grebely
2015-02-26

Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study

Helen McIlleron, Beatriz Grinsztejn, Anne F. Luetkemeyer, Ian Sanne, Diane Havlir

Human - wd:Q75155942

Welcome to Inventaire

the library of your friends and communities

learn more